JP6174572B2 - メトトレキサートを用いる免疫寛容の誘導 - Google Patents

メトトレキサートを用いる免疫寛容の誘導 Download PDF

Info

Publication number
JP6174572B2
JP6174572B2 JP2014511390A JP2014511390A JP6174572B2 JP 6174572 B2 JP6174572 B2 JP 6174572B2 JP 2014511390 A JP2014511390 A JP 2014511390A JP 2014511390 A JP2014511390 A JP 2014511390A JP 6174572 B2 JP6174572 B2 JP 6174572B2
Authority
JP
Japan
Prior art keywords
methotrexate
cells
matg
treatment
alemtuzumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014511390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513722A (ja
JP2014513722A5 (enExample
Inventor
アレグザンドラ・ジョーセフ
スーザン・リチャーズ
メラニー・ルゼック
リチャード・ガーマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47177257&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6174572(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2014513722A publication Critical patent/JP2014513722A/ja
Publication of JP2014513722A5 publication Critical patent/JP2014513722A5/ja
Application granted granted Critical
Publication of JP6174572B2 publication Critical patent/JP6174572B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
JP2014511390A 2011-05-16 2012-05-03 メトトレキサートを用いる免疫寛容の誘導 Active JP6174572B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486697P 2011-05-16 2011-05-16
US61/486,697 2011-05-16
PCT/US2012/036405 WO2012158362A1 (en) 2011-05-16 2012-05-03 Induction of immune tolerance by using methotrexate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017040046A Division JP6381707B2 (ja) 2011-05-16 2017-03-03 メトトレキサートを用いる免疫寛容の誘導

Publications (3)

Publication Number Publication Date
JP2014513722A JP2014513722A (ja) 2014-06-05
JP2014513722A5 JP2014513722A5 (enExample) 2015-06-25
JP6174572B2 true JP6174572B2 (ja) 2017-08-02

Family

ID=47177257

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014511390A Active JP6174572B2 (ja) 2011-05-16 2012-05-03 メトトレキサートを用いる免疫寛容の誘導
JP2017040046A Active JP6381707B2 (ja) 2011-05-16 2017-03-03 メトトレキサートを用いる免疫寛容の誘導
JP2018145564A Active JP6694020B2 (ja) 2011-05-16 2018-08-02 メトトレキサートを用いる免疫寛容の誘導

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017040046A Active JP6381707B2 (ja) 2011-05-16 2017-03-03 メトトレキサートを用いる免疫寛容の誘導
JP2018145564A Active JP6694020B2 (ja) 2011-05-16 2018-08-02 メトトレキサートを用いる免疫寛容の誘導

Country Status (28)

Country Link
US (3) US20140135337A1 (enExample)
EP (2) EP2709627B1 (enExample)
JP (3) JP6174572B2 (enExample)
KR (3) KR102316283B1 (enExample)
CN (4) CN109620830A (enExample)
AU (1) AU2012256281B2 (enExample)
BR (1) BR112013029501A2 (enExample)
CA (1) CA2835819A1 (enExample)
CL (1) CL2013003298A1 (enExample)
CO (1) CO6841993A2 (enExample)
DO (1) DOP2013000268A (enExample)
EC (1) ECSP13013081A (enExample)
ES (1) ES2836823T3 (enExample)
GT (1) GT201300278A (enExample)
IL (2) IL229245B (enExample)
MA (1) MA35165B1 (enExample)
MX (1) MX2013013445A (enExample)
MY (1) MY173304A (enExample)
NI (1) NI201300121A (enExample)
PE (1) PE20140469A1 (enExample)
PH (1) PH12013502256A1 (enExample)
PT (1) PT2709627T (enExample)
RU (1) RU2674036C2 (enExample)
SG (1) SG194802A1 (enExample)
TN (1) TN2013000472A1 (enExample)
UA (1) UA117556C2 (enExample)
WO (1) WO2012158362A1 (enExample)
ZA (1) ZA201308315B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11672802B2 (en) 2011-05-16 2023-06-13 Genzyme Corporation Induction of immune tolerance by using methotrexate

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809282B2 (en) * 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
CN107320734A (zh) 2011-04-29 2017-11-07 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
CN105307641A (zh) * 2013-05-03 2016-02-03 西莱克塔生物科技公司 用于降低不期望体液免疫应答的给药组合
ES2834129T3 (es) * 2013-06-04 2021-06-16 Selecta Biosciences Inc Administración repetida de agentes inmunoterapéuticos específicos de antígeno no inmunosupresores
EA201790551A1 (ru) 2014-09-07 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
JP2016213236A (ja) * 2015-04-30 2016-12-15 日東電工株式会社 半導体装置用フィルム、及び、半導体装置の製造方法
EP4599848A3 (en) 2017-03-11 2025-12-03 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2018209300A1 (en) * 2017-05-12 2018-11-15 Duke University Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy
TWI821227B (zh) * 2017-12-22 2023-11-11 美商健臻公司 胺甲喋呤誘發的免疫耐受性之生物標記
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase
EP4100120A1 (en) 2020-02-08 2022-12-14 Genzyme Corporation Compositions and methods for treating pompe disease
CN117295948A (zh) * 2021-05-13 2023-12-26 建新公司 淋巴细胞清除疗法后的继发性自身免疫的新型预测性生物标记物
TW202342057A (zh) * 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080325A (en) 1976-11-17 1978-03-21 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of methotrexate
US4558690A (en) 1982-01-26 1985-12-17 University Of Scranton Method of administration of chemotherapy to tumors
US5108987A (en) 1982-02-25 1992-04-28 Faulk Ward P Conjugates of proteins with anti-tumor agents
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
DE4000154A1 (de) 1990-01-04 1991-07-11 Symbiotec Gmbh Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
JP4927536B2 (ja) 2004-03-05 2012-05-09 電気化学工業株式会社 ヒアルロン酸−メトトレキサート結合体
US7884196B2 (en) 2004-10-06 2011-02-08 Oliver Lawless Vaccine composition comprising methylated DNA and immunomodulatory motifs
BRPI0708424A2 (pt) * 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
WO2008094937A2 (en) 2007-01-29 2008-08-07 Joslin Diabetes Center, Inc. Methods of modulating angiogenesis
WO2009073146A2 (en) * 2007-11-29 2009-06-11 Celgene Corporation Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
US7914785B2 (en) * 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) * 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
ES2632213T3 (es) 2008-10-08 2017-09-11 Cambridge Enterprise Limited Métodos y composiciones para diagnosticar y tratar una enfermedad autoinmunitaria que es secundaria con respecto a la esclerosis múltiple
KR20110093841A (ko) 2008-11-07 2011-08-18 4에스체 악티엔게젤샤프트 자가면역 질환의 치료를 위한 ｄｈｏｄｈ 억제제 및 메토트렉세이트를 포함하는 조합 요법
AU2012256281B2 (en) 2011-05-16 2017-06-15 Genzyme Corporation Induction of immune tolerance by using methotrexate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11672802B2 (en) 2011-05-16 2023-06-13 Genzyme Corporation Induction of immune tolerance by using methotrexate

Also Published As

Publication number Publication date
IL276879B (en) 2022-06-01
TN2013000472A1 (en) 2015-03-30
CL2013003298A1 (es) 2014-07-25
IL229245A0 (en) 2014-01-30
EP3824890A1 (en) 2021-05-26
IL276879A (en) 2020-10-29
KR20140040744A (ko) 2014-04-03
GT201300278A (es) 2015-02-12
KR102316283B1 (ko) 2021-10-21
MA35165B1 (fr) 2014-06-02
IL229245B (en) 2020-08-31
JP2014513722A (ja) 2014-06-05
KR102163285B1 (ko) 2020-10-08
WO2012158362A1 (en) 2012-11-22
ECSP13013081A (es) 2015-04-30
PT2709627T (pt) 2020-12-24
US11672802B2 (en) 2023-06-13
DOP2013000268A (es) 2014-01-31
KR20190132551A (ko) 2019-11-27
PH12013502256A1 (en) 2022-04-08
JP6694020B2 (ja) 2020-05-13
US20140135337A1 (en) 2014-05-15
RU2013155618A (ru) 2015-06-27
BR112013029501A2 (pt) 2017-01-24
CN113209288A (zh) 2021-08-06
NZ617575A (en) 2016-10-28
MY173304A (en) 2020-01-14
NZ716716A (en) 2018-06-29
CN103648501A (zh) 2014-03-19
US20230372347A1 (en) 2023-11-23
NZ742216A (en) 2018-10-26
MX2013013445A (es) 2014-07-28
CN110124039A (zh) 2019-08-16
AU2012256281A1 (en) 2013-11-28
UA117556C2 (uk) 2018-08-27
EP2709627A1 (en) 2014-03-26
EP2709627B1 (en) 2020-09-23
JP2017141236A (ja) 2017-08-17
SG194802A1 (en) 2013-12-30
JP2018184466A (ja) 2018-11-22
EP2709627A4 (en) 2014-11-12
AU2012256281B2 (en) 2017-06-15
US20200360385A1 (en) 2020-11-19
PE20140469A1 (es) 2014-04-23
NI201300121A (es) 2014-02-28
CN109620830A (zh) 2019-04-16
JP6381707B2 (ja) 2018-08-29
ES2836823T3 (es) 2021-06-28
CA2835819A1 (en) 2012-11-22
CO6841993A2 (es) 2014-01-20
RU2674036C2 (ru) 2018-12-04
ZA201308315B (en) 2014-07-30
KR20200116543A (ko) 2020-10-12

Similar Documents

Publication Publication Date Title
JP6381707B2 (ja) メトトレキサートを用いる免疫寛容の誘導
Rodrigo et al. Acute rejection following kidney transplantation: state-of-the-art and future perspectives
US20210236512A1 (en) Clozapine for the treatment of a immunoglobulin driven b cell disease
Joseph et al. Transient low-dose methotrexate induces tolerance to murine anti-thymocyte globulin and together they promote long-term allograft survival
HK40053503A (en) Induction of immune tolerance using methotrexate
HK40053628A (en) Induction of immune tolerance by using methotrexate
HK40012743A (en) Induction of immune tolerance by using methotrexate
HK40007634A (en) Induction of immune tolerance by using methotrexate
NZ716716B2 (en) Induction of immune tolerance by using methotrexate
HK1194668B (en) Induction of immune tolerance by using methotrexate
HK1194668A (en) Induction of immune tolerance by using methotrexate
OA16781A (en) Induction of immune tolerance by using methotrexate.
NZ617575B2 (en) Induction of immune tolerance by using methotrexate
NZ742216B2 (en) Induction of immune tolerance by using methotrexate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170303

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170613

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170706

R150 Certificate of patent or registration of utility model

Ref document number: 6174572

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250